168 related articles for article (PubMed ID: 12569373)
1. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.
Negoro S; Masuda N; Takada Y; Sugiura T; Kudoh S; Katakami N; Ariyoshi Y; Ohashi Y; Niitani H; Fukuoka M;
Br J Cancer; 2003 Feb; 88(3):335-41. PubMed ID: 12569373
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
Masuda N; Fukuoka M; Fujita A; Kurita Y; Tsuchiya S; Nagao K; Negoro S; Nishikawa H; Katakami N; Nakagawa K; Niitani H
Br J Cancer; 1998 Jul; 78(2):251-6. PubMed ID: 9683302
[TBL] [Abstract][Full Text] [Related]
3. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Masuda N
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
[TBL] [Abstract][Full Text] [Related]
5. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Georgoulias V; Kouroussis C; Agelidou A; Boukovinas I; Palamidas P; Stavrinidis E; Polyzos A; Syrigos K; Veslemes M; Toubis M; Ardavanis A; Tselepatiotis E; Vlachonikolis I;
Br J Cancer; 2004 Aug; 91(3):482-8. PubMed ID: 15238986
[TBL] [Abstract][Full Text] [Related]
7. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer.
Oka M; Fukuda M; Fukuda M; Kinoshita A; Kuba M; Ichiki M; Rikimaru T; Soda H; Takatani H; Narasaki F; Nagashima S; Nakamura Y; Hayashi N; Kohno S
Eur J Cancer; 2001 Jul; 37(11):1359-65. PubMed ID: 11435065
[TBL] [Abstract][Full Text] [Related]
9. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'.
Pérol M; Guérin JC; Thomas P; Poirier R; Carles P; Robinet G; Kleisbauer JP; Paillotin D; Vergnenègre A; Balmes P; Touron D; Grivaux M; Pham E
Lung Cancer; 1996 Feb; 14(1):119-34. PubMed ID: 8696715
[TBL] [Abstract][Full Text] [Related]
10. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer.
Kakolyris S; Kouroussis C; Souglakos J; Agelaki S; Kalbakis K; Vardakis N; Vamvakas L; Georgoulias V
Lung Cancer; 2001 Dec; 34 Suppl 4():S71-6. PubMed ID: 11742707
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.
Takeda Y; Tsuduki E; Izumi S; Hojo M; Kamimura M; Naka G; Kobayashi K; Kudo K
Br J Cancer; 2005 Dec; 93(12):1341-9. PubMed ID: 16288302
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
DeVore RF; Johnson DH; Crawford J; Garst J; Dimery IW; Eckardt J; Eckhardt SG; Elfring GL; Schaaf LJ; Hanover CK; Miller LL
J Clin Oncol; 1999 Sep; 17(9):2710-20. PubMed ID: 10561345
[TBL] [Abstract][Full Text] [Related]
14. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.
Cardenal F; Domine M; Massutí B; Carrato A; Felip E; Garrido P; Juan O; Artal A; Barneto I; López-Vivanco G; Balcells M; Rosell R
Lung Cancer; 2003 Feb; 39(2):201-7. PubMed ID: 12581574
[TBL] [Abstract][Full Text] [Related]
15. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
Georgoulias V; Agelidou A; Syrigos K; Rapti A; Agelidou M; Nikolakopoulos J; Polyzos A; Athanasiadis A; Tselepatiotis E; Androulakis N; Kalbakis K; Samonis G; Mavroudis D
Br J Cancer; 2005 Oct; 93(7):763-9. PubMed ID: 16175189
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer.
Takeda K; Takifuji N; Uejima H; Yoshimura N; Terakawa K; Negoro S
Lung Cancer; 2002 Dec; 38(3):303-8. PubMed ID: 12445753
[TBL] [Abstract][Full Text] [Related]
17. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments].
Yokoyama A; Kurita Y; Saijo N; Tamura T; Noda K; Shimokata K; Matsuda T
Br J Cancer; 1998 Jul; 78(2):257-62. PubMed ID: 9683303
[TBL] [Abstract][Full Text] [Related]
18. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
19. Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
Kakolyris S; Kouroussis C; Kalbakis K; Mavroudis D; Souglakos J; Nvardakis ; Kremos S; Georgoulias V
Ann Oncol; 2000 Jun; 11(6):757-60. PubMed ID: 10942068
[TBL] [Abstract][Full Text] [Related]
20. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
